ArticleAmerican heart journal2019
Heart failure and adverse heart failure outcomes among persons living with HIV in a US tertiary medical center.
Article in American heart journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Heart Failure Risk and Events in People With HIV: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).Circulation. Heart failure · 2026Trial
- Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial.The Journal of infectious diseases · 2020 · on this mapTrial
- Thirty-Day Readmission Risk Among Adults Hospitalized for Heart Failure or Acute Myocardial Infarction With and Without HIV.Open forum infectious diseases · 2025Article
- HIV-Associated Heart Failure: Phenotypes and Clinical Outcomes in a Safety-Net Setting.Journal of the American Heart Association · 2024Article
- HIV-Associated Heart Failure: Phenotypes and Clinical Outcomes in a Safety-Net Setting.medRxiv : the preprint server for health sciences · 2024Article
- Adipose Tissue Dysfunction and Energy Balance Paradigms in People Living With HIV.Endocrine reviews · 2024Review
- Prevention of heart failure, tachyarrhythmias and sudden cardiac death in HIV.Current opinion in HIV and AIDS · 2022Review
- Mortality and length of stay among HIV patients hospitalized for heart failure: A multicenter retrospective study.American heart journal plus : cardiology research and practice · 2022Article
- Article
- Coronary Vasculature and Myocardial Structure in HIV: Physiologic Insights From the Renin-Angiotensin-Aldosterone System.The Journal of clinical endocrinology and metabolism · 2021Review
- Human immunodeficiency virus infection and risks of morbidity and death in adults with incident heart failure.European heart journal open · 2021Article
- Review
- Amino-terminal Pro-B-Type Natriuretic Peptide Among Patients Living With Both Human Immunodeficiency Virus and Heart Failure.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Heart Failure Outcomes and Associated Factors Among Veterans With Human Immunodeficiency Virus Infection.JACC. Heart failure · 2020Article
- Heart Failure among People with HIV: Evolving Risks, Mechanisms, and Preventive Considerations.Current HIV/AIDS reports · 2019Review
- Advance directive screening among veterans with incident heart failure: Comparisons among people aging with and without HIV.Heart & lung : the journal of critical careArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundPersons living with HIV (PLHIV) have an increased risk of heart failure (HF). However, little is known about outcomes among PLHIV with HF. The study aim was to compare HF outcomes among PLHIV with HF versus individuals without HIV with HF.
methodsOur cohort included 2,308 individuals admitted with decompensated HF. We compared baseline characteristics, 30-day HF readmission, and cardiovascular (CV) and all-cause mortality. Within PLHIV, we assessed outcomes stratified between CD4 count and viral load (VL), and tested the association between traditional and HIV-specific parameters with 30-day HF readmission.
resultsThere were 374 (16%) PLHIV with HF. Among PLHIV, 92% were on antiretroviral therapy and 63% had a VL <200 copies/mL. Groups were similar with respect to age, sex, race/ethnicity, and CV risk factors. In follow-up, PLHIV had increased 30-day HF readmission (49% vs 32%) and CV (26% vs 13.5%) and all-cause mortality rates (38% vs 22%). Among PLHIV, cocaine use, HIV-specific parameters (CD4, VL), and coronary artery disease were predictors of 30-day HF readmission. Specifically, among PLHIV, those with detectable VL had higher 30-day HF readmission and CV mortality, whereas PLHIV with undetectable VL had a similar 30-day HF readmission rate and CV mortality to uninfected controls with HF. Similar outcomes were observed across strata of left ventricular ejection fraction and by CD4.
conclusionsPLHIV with a low CD4 count or detectable VL have an increased 30-day HF readmission rate as well as increased CV and all-cause mortality. In contrast, PLHIV with a higher CD4 count and undetectable VL have similar HF outcomes to uninfected controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.